• Home
  • About Us
    • About Us
    • Leadership Team
  • Science
    • Biologics
    • Biomanufacturing
    • Pipeline
  • Investors
    • Overview
    • SEC Filings
    • Press Releases
    • Presentations
    • Corporate Governance
    • Investor Resources
      semaglutide
      • Email Alerts
      • FAQs
      • Tax Documents
  • Careers
  • Contact Us

Tivic Reports Third Quarter 2024 Financial Results and Provides Business Update

Nov 14, 2024 | Press Releases

Pre-recorded Conference Call to Follow at 1:30 p.m. PDT/4:30 p.m EDT FREMONT, Calif. – Tivic Health® Systems, Inc. (Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced third quarter and nine-months...

Enrollment Complete in Tivic Health Optimization Study for its Non-Invasive Vagus Nerve Stimulation Device

Nov 14, 2024 | Press Releases

FREMONT, Calif. – Tivic Health® Systems, Inc. (Nasdaq: TIVC), a health tech company developing and commercializing bioelectronic medicine, announced today that full enrollment has been completed in the optimization study for Tivic Health’s patent...

Tivic Health Validates European Patents in Great Britain, Germany, and France

Nov 12, 2024 | Press Releases

Patents cover methods used to identify key treatment points and dynamically personalize simulation FREMONT, Calif. – Tivic Health® Systems, Inc. (Nasdaq: TIVC), a health tech company developing and commercializing bioelectronic medicinal devices, announced...

Tivic Health Systems, Inc. to Report Third Quarter 2024 Financial Results on November 14

Nov 7, 2024 | Press Releases

– Conference Call and Webcast to Follow at 1:30 p.m. PST/4:30 p.m. EST – FREMONT, Calif. – Tivic Health® Systems, Inc. (Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced it will report...

First Subject Enrolled in Tivic Health’s Optimization Study for its Non-Invasive Vagus Nerve Stimulation Device

Oct 29, 2024 | Press Releases

FREMONT, Calif. – Tivic Health® Systems, Inc. (Nasdaq: TIVC), a health tech company developing and commercializing bioelectronic medicine, announced today that the first study subject has been enrolled in the optimization study for Tivic Health’s...
« Older Entries
Next Entries »

Recent Posts

  • Valion Bio Welcomes Former U.S. Army Regulatory Leader and Biotech CEO Dr. Armand Balboni as Advisor in Run-up to Entolimod Therapeutic Efficacy Data Readout
  • Valion Bio Reports Completion of 200-Liter Entolimod Production Run; Material Supplying Ongoing AFRRI Study
  • Valion Bio Reinforces Commitment to American Troops; Discusses Entolimod with Attendees at RW Baird’s National Security Conference
  • Valion Bio Advancing Entolimod into U.S. Government-Funded Therapeutic Efficacy Study Following Positive Safety Results
  • Valion Bio Announces Positive Safety Results From U.S. Government-Funded Entolimod Study, Paving Way For Therapeutic Efficacy Evaluation

Recent Comments

No comments to show.
©2026 Valion Bio

Privacy Policy

For ClearUP customer questions regarding warranty or other device inquiries, please reach out to customerservice@tivichealth.com.